BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dalekos GN, Koskinas J, Papatheodoridis GV. Hellenic Association for the Study of the Liver Clinical Practice Guidelines: Autoimmune hepatitis. Ann Gastroenterol 2019;32:1-23. [PMID: 30598587 DOI: 10.20524/aog.2018.0330] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
Number Citing Articles
1 Rigopoulou EI, Dalekos GN. Current Trends and Characteristics of Hepatocellular Carcinoma in Patients with Autoimmune Liver Diseases. Cancers (Basel) 2021;13:1023. [PMID: 33804480 DOI: 10.3390/cancers13051023] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
2 Arvaniti P, Giannoulis G, Gabeta S, Zachou K, Koukoulis GK, Dalekos GN. Belimumab is a promising third-line treatment option for refractory autoimmune hepatitis. JHEP Rep 2020;2:100123. [PMID: 32671332 DOI: 10.1016/j.jhepr.2020.100123] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
3 Sarcognato S, Sacchi D, Grillo F, Cazzagon N, Fabris L, Cadamuro M, Cataldo I, Covelli C, Mangia A, Guido M. Autoimmune biliary diseases: primary biliary cholangitis and primary sclerosing cholangitis. Pathologica 2021;113:170-84. [PMID: 34294935 DOI: 10.32074/1591-951X-245] [Reference Citation Analysis]
4 Lotowska JM, Sobaniec-Lotowska ME, Sobaniec P. Ultrastructural Profile Combined with Immunohistochemistry of a Hepatic Progenitor Cell Line in Pediatric Autoimmune Hepatitis: New Insights into the Morphological Pattern of the Disease. Cells 2021;10:1899. [PMID: 34440668 DOI: 10.3390/cells10081899] [Reference Citation Analysis]
5 Gatselis NK, Azariadis K, Lyberopoulou A, Dalekos GN. Programmed cell death-1 rs11568821 and interleukin-28B rs12979860 polymorphisms in autoimmune hepatitis. J Transl Autoimmun 2021;4:100126. [PMID: 34632357 DOI: 10.1016/j.jtauto.2021.100126] [Reference Citation Analysis]
6 Zachou K, Arvaniti P, Lyberopoulou A, Dalekos GN. Impact of genetic and environmental factors on autoimmune hepatitis. J Transl Autoimmun 2021;4:100125. [PMID: 34622188 DOI: 10.1016/j.jtauto.2021.100125] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Tasneem AA, Luck NH. Autoimmune Hepatitis: Clinical Characteristics and Predictors of Biochemical Response to Treatment. J Transl Int Med 2020;8:106-11. [PMID: 32983933 DOI: 10.2478/jtim-2020-0016] [Reference Citation Analysis]
8 Azariadis K, Gatselis NK, Koukoulis GK, Dalekos GN. Glycogenic hepatopathy as a cause of severe deranged liver enzymes in a young patient with type 1 diabetes mellitus. BMJ Case Rep 2019;12:e228524. [PMID: 30898943 DOI: 10.1136/bcr-2018-228524] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
9 Muñoz-sánchez G, Pérez-isidro A, Ortiz de Landazuri I, López-gómez A, Bravo-gallego LY, Garcia-ormaechea M, Julià MR, Viñas O, Ruiz-ortiz E; on behalf of the 2020 GEAI-SEI Workshop Participants. Working Algorithms and Detection Methods of Autoantibodies in Autoimmune Liver Disease: A Nationwide Study. Diagnostics 2022;12:697. [DOI: 10.3390/diagnostics12030697] [Reference Citation Analysis]
10 Çavuş B, Akyuz F, İliaz R, Atasoy A, Akyuz U, Demir K, Besisik F, Kaymakoglu S. Is there any predictor for relapse after treatment withdrawal in autoimmune hepatitis patients in the real life? Int J Immunopathol Pharmacol 2022;36:3946320221077860. [PMID: 35171719 DOI: 10.1177/03946320221077860] [Reference Citation Analysis]